PROCHLORPERAZINE MALEATE MARKET ANALYSIS

Market Challenges And Opportunities

Prochlorperazine Maleate Market Drivers:

• Increasing Prevalence of Nausea and Vomiting: Nausea and vomiting are common symptoms experienced by patients undergoing chemotherapy, surgery, and other medical procedures. With the growing prevalence of chronic diseases and an aging population, the number of individuals requiring antiemetic therapy is increasing. Prochlorperazine maleate, with its proven effectiveness, becomes a preferred choice for healthcare providers in managing these symptoms, leading to market growth. For instance, according to the data published by Science Direct in October 2021, a study conducted to determine the prevalence and coping strategies for postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting (PDNV) in patients undergoing outpatient surgery, it was found that 30.6% of the patients had PONV and 26.3% had PDNV.
• Increasing Product Launches: Increasing product launches by market players is expected to propel market growth over the forecast period. For instance, on March 20, 2023, Glenmark Pharmaceuticals, a pharmaceutical company based in India, received approval from the U.S. Food and Drug Administration (FDA) for Prochlorperazine Maleate Tablets USP, 5 mg, and 10 mg.

Prochlorperazine Maleate Market Restraints:

• Availability of Alternative Therapies: There are alternative therapies and medications available for managing nausea and vomiting, which can limit the market potential of prochlorperazine maleate. Other antiemetic drugs, such as 5-HT3 receptor antagonists or NK-1 receptor antagonists, may be preferred in certain clinical scenarios based on patient characteristics or specific indications. The availability of these alternatives may influence the prescribing patterns and market demand for prochlorperazine maleate.
• Increasing product launches by the market players will aid in the market growth over the forecast period.

Prochlorperazine Maleate Market Opportunities:

• Increasing Prevalence of Mental Disorder: Increasing prevalence of mental illness is expected to propel market growth over the forecast period. For instance, according to the data published by the World Health Organization on January 10, 2022, schizophrenia affects approximately 24 million people, or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults.
• Expansion into Emerging Markets: There is a significant opportunity for prochlorperazine maleate manufacturers to expand their presence in emerging markets. Regions such as Asia Pacific, Latin America, and the Middle East have growing healthcare infrastructure, increasing access to medical services, and a rising prevalence of conditions requiring antiemetic therapy. By targeting these markets and adapting to local regulations and preferences, companies can tap into new customer bases and drive market growth.